Nurix Therapeutics, Inc.
NRIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001549595
In the last 90 days, Nurix Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 211 institutions reported holding it in 13F filings for Q2 2026, worth $2.84B in total; ARK Invest is the only superinvestor holding it.
Q2 2022 vs. Q1 2022
How the institutions holding Nurix Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 117 | 2 | 106 | −9 |
| Shares | 40.4M | 37.8K | 45.0M | +4.65M (+11.5%) |
| Value | $565.6M | $529.0K | $568.4M | +$3.32M (+0.6%) |
2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held Nurix Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Deep Track Capital, LP | 2,436,164 | $30.9M | 2.13% |
| Jackson Creek Investment Advisors LLC | 55,057 | $879.0K | 0.36% |
| ClariVest Asset Management LLC | 49,700 | $630.0K | 0.03% |
| Raymond James & Associates | 41,279 | $523.0K | 0.00% |
| SG Americas Securities, LLC | 34,221 | $434.0K | 0.01% |
| Bank of Montreal | 24,104 | $289.0K | 0.00% |
| State Board of Administration of Florida Retirement System | 22,691 | $287.0K | 0.00% |
| Thrivent Financial for Lutherans | 15,177 | $192.0K | 0.00% |
| Algert Global LLC | 14,980 | $190.0K | 0.01% |
| Mirae Asset Global Investments Co., Ltd. | 10,098 | $128.0K | 0.00% |
| Fred Alger Management, LLC | 7,306 | $93.0K | 0.00% |
| Parallel Advisors, LLC | 30 | $0 | 0.00% |
| Rockefeller Capital Management L.P. | 57 | $0 | 0.00% |
Sold out (22)
Institutions that held Nurix Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| EcoR1 Capital, LLC | 254,473 | $3.56M |
| Woodline Partners LP | 219,281 | $3.07M |
| Citadel Advisors LLC | 211,783 | $2.97M |
| Regents of the University of California | 204,123 | $2.86M |
| Alyeska Investment Group, L.P. | 120,750 | $1.69M |
| Two Sigma Investments, LP | 91,335 | $1.28M |
| Point72 Asset Management, L.P. | 69,850 | $979.0K |
| Qube Research & Technologies Ltd | 33,003 | $462.0K |
| Laurion Capital Management LP | 28,470 | $399.0K |
| Parkman Healthcare Partners LLC | 20,663 | $289.0K |
| Squarepoint Ops LLC | 20,516 | $287.0K |
| Gsa Capital Partners LLP | 15,963 | $224.0K |
| ExodusPoint Capital Management, LP | 15,034 | $211.0K |
| Graham Capital Management, L.P. | 12,350 | $173.0K |
| Two Sigma Advisers, LP | 12,200 | $171.0K |
| HSBC Holdings PLC | 11,615 | $165.0K |
| ProShare Advisors LLC | 10,489 | $148.0K |
| Point72 Hong Kong Ltd | 1,109 | $16.0K |
| TCI Wealth Advisors, Inc. | 269 | $4.00K |
| EMC Capital Management | 288 | $3.00K |
| Signaturefd, LLC | 48 | $1.00K |
| Covestor Ltd | 13 | $0 |
Not filed for Q2 2022 yet (2)
Institutions that held Nurix Therapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Susquehanna Fundamental Investments, LLC | 32,769 | $459.0K |
| Amalgamated Financial Corp. | 4,981 | $70.0K |